Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Chart Industries Inc (GTLS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Chart Industries Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Chart Industries Inc trades at $209.87 (market cap $10.05B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4× Chart Industries Inc's market cap, and Chart Industries Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | GTLS | |
|---|---|---|
Market Cap | $39.89B | $10.05B |
Sector | Health | Technology |
52-Week High | $491.22 | $209.87 |
52-Week Low | $278.09 | $164.90 |
Enterprise Value | $38.15B | $13.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
GTLS trades at $209.87, up 0.13% on the day, with a bullish technical outlook from moving averages but overbought RSI signals. The company reported $4.26B revenue in 2025 but missed EPS estimates for three consecutive quarters, with negative net income margin and ROE. Recent news highlights Baker Hughes' pending $13.6B acquisition, which secured EU antitrust approval in July 2026, providing a significant catalyst.
The stock's outlook is supported by strong analyst buy ratings (54%) and the acquisition premium, but risks include consistent earnings misses, profitability challenges, and integration execution. Valuation appears stretched with a P/E of 629.67, suggesting cautious optimism hinges on deal completion and margin improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Chart Industries Inc
Chart Industries is a leading manufacturer of highly engineered cryogenic equipment. Its products are used throughout the liquid gas supply chain, including clean energy applications like hydrogen and LNG.
Read more on GTLS →
